-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Previously, it was reported that ErSO, a small molecule drug from Bayer, has a 95% to 100% success rate for the treatment of cancer cells in animals
This therapy ErSO is a new drug developed by researchers at the University of Illinois in the United States.
In September 2020, Bayer signed an agreement to purchase the development license for the drug for US$370 million and cooperated with Arizona-based Systems Oncology to develop the drug
However, according to the latest reports, since the partnership between the two companies is no longer effective, the two companies' cooperation project on the tumor therapy has also reached a deadlock
Metastatic estrogen receptor-positive breast cancer is the most common type of breast cancer, and there is currently no cure.
ErSO Activism manager Danny Goss expressed his disappointment.
At the same time, Professor Shapiro and his team said they will continue to study ErSO therapy
Reference source:
1.
2.